Lead candidate Nefecon (a targeted-release budesonide formulation) is positioned, if approved, to transform the treatment of IgAN. Today, the 130,000–150,000 people estimated to suffer from this ...

花旗发表报告指，与云顶新耀举行了最新会议，管理层指导2025年销售额为14亿元，包括Nefecon的10亿元和Xerava的4亿元。而Nefecon已成功纳入国家医保。

Nefecon is a formulation of the established immunology drug budesonide, which targets the Peyer’s patches that are over-active in patients with IgAN. The antibodies produced as a result lodge in ...

Nefecon takes the form of an encapsulated oral formulation of the established corticosteroid budesonide, which Calliditas says provides localised delivery of the drug to the ileum in the ...